TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15231982

Group type: EXPERIMENTAL
Intervention: Once-Daily Dosing (ODD) of aminoglycosides
Number of subjects: 1949

Group type: COMPARATOR
Intervention: Multiple Daily Dosing (MDD) of aminoglycosides
Number of subjects: 1949
Study: 11752995

Group type: EXPERIMENTAL
Intervention: Simulator-assisted learning
Number of subjects: 144

Group type: COMPARATOR
Intervention: Video-assisted learning
Number of subjects: 144
Study: 9578507

Group type: EXPERIMENTAL
Intervention: Daily s.c. injections of 0.9 mg/m2 hGH
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 34
Study: 7715582

Group type: EXPERIMENTAL
Intervention: Antioxidant treatment with selenium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scavenger treatment
Number of subjects: 0
Study: 2116042

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 77

Group type: COMPARATOR
Intervention: GST
Number of subjects: 77
Study: 619607

Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) at a concentration of 20 microgram/ml
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control solution of orange juice
Number of subjects: 11
Study: 30701613

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (380 mg intramuscularly injected every four weeks)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (flexible 4-16 mg sublingual doses daily)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Switching from buprenorphine-naloxone to extended-release naltrexone
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 143
Study: 28302527

Group type: EXPERIMENTAL
Intervention: Multiple plastic stents (MPSs)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Covered self-expandable metal stents (cSEMSs)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 26471464

Group type: EXPERIMENTAL
Intervention: Bexident Post (BP) gel, used three times daily after tooth extraction.
Number of subjects: 47

Group type: COMPARATOR
Intervention: Bicarbonate (BC) oral rinse, used three times daily after tooth extraction.
Number of subjects: 47
Study: 22733001

Group type: EXPERIMENTAL
Intervention: Wild blueberry drink (25 g freeze-dried powder providing 375 mg of ACNs)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 18
Study: 20832955

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 33
Study: 19923636

Group type: EXPERIMENTAL
Intervention: Diclectin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral solutions of doxylamine succinate and pyridoxine hydrochloride
Number of subjects: 18
Study: 15860696

Group type: EXPERIMENTAL
Intervention: IV corticosteroids
Number of subjects: 1847

Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 1847
Study: 11807721

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of a single DHFR mutation (Arg-59) with a single DHPS mutation (Glu-540)
Number of subjects: 0
Study: 10628575

Group type: EXPERIMENTAL
Intervention: Depression Education Program (2 4-hour interactive workshops)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study: 7549079

Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin, beta-blockers, converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitrates and magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer antithrombotic and antiplatelet agents (hirudin, glycoprotein IIb/IIIa receptor antagonists)
Number of subjects: 0
Study: 1853532

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study: 6975823

Group type: EXPERIMENTAL
Intervention: Trimethoprim (300 mg once a day for seven days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole, two tablets twice a day for seven days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimethoprim and co-trimoxazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 0
Study: 31766743

Group type: EXPERIMENTAL
Intervention: l-Carnitine administration (200 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-Carnitine administration (50-100 mg/kg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-Carnitine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: l-Carnitine administration in ASD associated with genetic disorders
Number of subjects: 0
Study: 27956393

Group type: EXPERIMENTAL
Intervention: Video plus sucrose plus liposomal lidocaine
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Parent-directed video education about infant soothing
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Video plus sucrose
Number of subjects: 352
Study: 25849853

Group type: EXPERIMENTAL
Intervention: Isokinetic and aerobic exercises
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 23513249

Group type: COMPARATOR
Intervention: Continuous oxygen flow by standard nasal cannula (CFNC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pulse demand oxygen delivery (DOD)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pendant reservoir cannula (PRC)
Number of subjects: 59
Study: 21546089

Group type: EXPERIMENTAL
Intervention: 0.5 mg VEGF Trap‐Eye every 4 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2 mg VEGF Trap‐Eye every 4 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then every 8 weeks
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2 mg VEGF Trap‐Eye for 3 initial monthly doses and then on an as‐needed (PRN) basis
Number of subjects: 221

Group type: COMPARATOR
Intervention: macular laser photocoagulation
Number of subjects: 221
Study: 19706572

Group type: COMPARATOR
Intervention: Hospital crib
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Car bed
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Car seat
Number of subjects: 200
Study: 17278206

Group type: EXPERIMENTAL
Intervention: Iron supplementation and anti-H pylori therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Iron supplementation only
Number of subjects: 22
Study: 15083479

Group type: EXPERIMENTAL
Intervention: Bayesian, counterfactual approach using data augmentation (DA) algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Likelihood-based, counterfactual approach based on the EM algorithm
Number of subjects: 0
Study: 11597814

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (HFRT) - 59.4 Gy in 54 1.1-Gy twice daily fractions
Number of subjects: 490

Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (CFRT) - 50.4 Gy in 28 1.8-Gy daily fractions
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: HFRT
Number of subjects: 490

Group type: COMPARATOR
Intervention: CFRT
Number of subjects: 490
Study: 9588436

Group type: EXPERIMENTAL
Intervention: 5 mg of donepezil hydrochloride
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: 10 mg of donepezil hydrochloride
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 7985937

Group type: EXPERIMENTAL
Intervention: Protocol A (standard therapy regimen)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Protocol B (standard therapy regimen plus plasmapheresis)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Protocol C (standard therapy regimen plus pulse methylprednisolone)
Number of subjects: 18
Study: 2574553

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg every 12 hours
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg each day
Number of subjects: 26

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 26
Study: 1102656

Group type: EXPERIMENTAL
Intervention: alexidine mouthwash
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo mouthwash
Number of subjects: 45
Study: 31794542

Group type: EXPERIMENTAL
Intervention: Microblepharon exfoliation
Number of subjects: 30
Study: 31312144

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (30 μg ethinyl estradiol)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives (20 μg ethinyl estradiol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: NOC (non-OC users)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both OC and NOC groups
Number of subjects: 28
Study: 28291675

Group type: EXPERIMENTAL
Intervention: Cerebral protection device (CPD) usage by vascular surgeons
Number of subjects: 831

Group type: COMPARATOR
Intervention: Choice of stent and CPD based on plaque characteristics
Number of subjects: 831
Study: 24171791

Group type: EXPERIMENTAL
Intervention: 1.0% sodium‐Hyaluronate
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intraocular irrigating solution
Number of subjects: 38
Study: 23302232

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) using the transarterial CoreValve System (Medtronic Inc.)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 280
Study: 21227945

Group type: EXPERIMENTAL
Intervention: ExAmen (n = 24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: ExOvul (n = 26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ExAmen
Number of subjects: 50

Group type: COMPARATOR
Intervention: ExOvul
Number of subjects: 50
Study: 16443353

Group type: EXPERIMENTAL
Intervention: Ciclesonide (80 or 160 microg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone (100 microg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide (160 microg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciclesonide and Fluticasone (both groups)
Number of subjects: 0
Study: 12960650

Group type: EXPERIMENTAL
Intervention: Erythromycin (1.5 mg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 10780503

Group type: EXPERIMENTAL
Intervention: Questionnaire of Smoking Urges (QSU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary reinforcement (puffs on a cigarette)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary reinforcement (tokens for puffs on a cigarette)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PR performance under primary reinforcement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlations between PR and QSU measures
Number of subjects: 0
Study: 8739820

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 55
Study: 1831005

Group type: EXPERIMENTAL
Intervention: Dermal pretreatment with 0.5% hydrocortisone cream
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dermal pretreatment with magnesium-aluminum hydroxide suspension
Number of subjects: 10

Group type: COMPARATOR
Intervention: Transdermal patch alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All treatments (hydrocortisone, magnesium-aluminum hydroxide, patch alone)
Number of subjects: 10
Study: 7049351

Group type: EXPERIMENTAL
Intervention: Ascorbic acid, 3 g/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 31481688

Group type: EXPERIMENTAL
Intervention: Active rTMS to left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 19
Study: 28499979

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 26541921

Group type: EXPERIMENTAL
Intervention: Multivessel revascularization
Number of subjects: 664

Group type: COMPARATOR
Intervention: No multivessel revascularization
Number of subjects: 664
Study: 24216182

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (MSCs) combined with cord blood (CB)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 22

Group type: COMPARATOR
Intervention: Disease-free survival
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cumulative incidence of tumor relapse
Number of subjects: 22
Study: 22113980

Group type: EXPERIMENTAL
Intervention: Navigation template implantation (NT group, n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional THA (control group, n=11)
Number of subjects: 22
Study: 19378912

Group type: EXPERIMENTAL
Intervention: Daily supine cycle exercise (Exercise group; N = 14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No exercise (Rest group; N = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (Exercise and Rest)
Number of subjects: 21
Study: 17387462

Group type: EXPERIMENTAL
Intervention: Ximelagatran co-administered with azithromycin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ximelagatran co-administered with cefuroxime
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ximelagatran co-administered with amoxicillin, doxycycline, or ciprofloxacin
Number of subjects: 80
Study: 15467565

Group type: EXPERIMENTAL
Intervention: Planned cesarean section
Number of subjects: 917

Group type: COMPARATOR
Intervention: Planned vaginal birth
Number of subjects: 917
Study: 11441386

Group type: EXPERIMENTAL
Intervention: Arm Ability Training (AAT) with knowledge of results
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arm Ability Training (AAT) without knowledge of results
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Arm Ability Training (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Arm Ability Training (AAT)
Number of subjects: 60
Study: 11103296

Group type: EXPERIMENTAL
Intervention: Black tea without milk
Number of subjects: 9

Group type: COMPARATOR
Intervention: Black tea with milk
Number of subjects: 9

Group type: COMPARATOR
Intervention: No tea
Number of subjects: 9
Study: 9049513

Group type: EXPERIMENTAL
Intervention: Nisoldipine coat-core (nisoldipine-CC)
Number of subjects: 542
Study: 8396103

Group type: EXPERIMENTAL
Intervention: Azithromycin, single daily dose of 10 mg/kg (maximum 500 mg) for three days (n = 46)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Erythromycin ethylsuccinate, 30‐50 mg/kg daily in three divided doses for ten days (n = 47)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 93
Study: 2424759

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg b.i.d.
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 301
Study: 30383633

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management intervention over 10 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 28
Study: 27181507

Group type: EXPERIMENTAL
Intervention: MenACWY‐CRM
Number of subjects: 202

Group type: COMPARATOR
Intervention: MenACWY‐TT
Number of subjects: 202
Study: 24170106

Group type: EXPERIMENTAL
Intervention: LB03002 (once-weekly)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Daily GH (daily)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: LB03002 (once-weekly throughout)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: LB03002 (switched to)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: LB03002
Number of subjects: 178
Study: 22874850

Group type: EXPERIMENTAL
Intervention: Semi-synthetic DTwP vaccine
Number of subjects: 331

Group type: COMPARATOR
Intervention: Routine DTwP vaccine
Number of subjects: 331
Study: 20517329

Group type: EXPERIMENTAL
Intervention: Q‐500 (500 mg/day)
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Q‐1000 (1000 mg/day)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002
Study: 18281659

Group type: EXPERIMENTAL
Intervention: Carboplatin and etoposide with oblimersen (arm A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Carboplatin and etoposide without oblimersen (arm B)
Number of subjects: 56
Study: 15885050

Group type: EXPERIMENTAL
Intervention: Tolperisone (300-900 mg daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tolperisone
Number of subjects: 120
Study: 12646342

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 580
Study: 10474578

Group type: EXPERIMENTAL
Intervention: Asthma clinics (three sessions over six months involving nurse counselling, education about asthma management, spirometry, and consultation with the general practitioner)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard general practice care
Number of subjects: 195
Study: 8707025

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg o.d.
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nifedipine AR 20 mg b.d.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1679569

Group type: EXPERIMENTAL
Intervention: Combined therapy (azathioprine + sulfasalazine)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sulfasalazine
Number of subjects: 140
Study: 30127297

Group type: EXPERIMENTAL
Intervention: High concentrate omega-3 (MF4637) for 24 weeks
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 26784000

Group type: EXPERIMENTAL
Intervention: Ofatumumab
Number of subjects: 122

Group type: COMPARATOR
Intervention: Physicians' choice
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Extended ofatumumab treatment
Number of subjects: 122
Study: 24798419

Group type: EXPERIMENTAL
Intervention: Training course for general practice nurses (16-hour Self-determination theory-based course over 10 months)
Number of subjects: 4034
Study: 22558609

Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 300 mg in the morning and 600 mg in the evening for 7 days, then 300 mg twice a day for 7 more days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ibuprofen 600 mg three times a day for 2 weeks
Number of subjects: 24
Study: 20438630

Group type: EXPERIMENTAL
Intervention: Humalog Mix 25
Number of subjects: 11

Group type: COMPARATOR
Intervention: Humalog Mix 50
Number of subjects: 11
Study: 19040016

Group type: EXPERIMENTAL
Intervention: Early submaximal cardiopulmonary exercise test (CPET) and cardiac rehabilitation for 3 months
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group conducting exercise according to their needs
Number of subjects: 94
Study: 16741684

Group type: EXPERIMENTAL
Intervention: Penn Resiliency Program (PRP)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 271
Study: 12679767

Group type: EXPERIMENTAL
Intervention: Tirofiban infusion
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 11029126

Group type: EXPERIMENTAL
Intervention: 0.1 mg kg(‐1) cisatracurium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.15 mg kg(‐1) cisatracurium
Number of subjects: 30
Study: 8717544

Group type: EXPERIMENTAL
Intervention: Dual energy X-ray absorptiometry (DXA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DXA with relevant site-specific parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-quality operator performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DXA measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed analytic methods
Number of subjects: 0
Study: 1305331

Group type: EXPERIMENTAL
Intervention: 500 micrograms sublingual GTN
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 5 mg buccal GTN
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 4066577

Group type: EXPERIMENTAL
Intervention: Activity group (A)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 89
Study: 31145432

Group type: EXPERIMENTAL
Intervention: Static treatment protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic treatment protocol
Number of subjects: 0
Study: 29447199

Group type: EXPERIMENTAL
Intervention: HRV-16
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30592818

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 76

Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 76

Group type: COMPARATOR
Intervention: Both groups (Sevoflurane and Desflurane)
Number of subjects: 76
Study: 24785750

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (natural healing)
Number of subjects: 20
Study: 22334369

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30-45 mg/day plus standard care (peginterferon alpha-2a plus ribavirin for 48 weeks)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (peginterferon alpha-2a plus ribavirin for 48 weeks)
Number of subjects: 150
Study: 20803300

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) administered twice daily, titrated from 250 to 2,000 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo administered twice daily
Number of subjects: 32
Study: 17937961

Group type: EXPERIMENTAL
Intervention: 4 mg tolterodine extended release
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 8 mg tolterodine extended release
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16110271

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 12375315

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) coadministered with Hydroxychloroquine (HCQ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ) alone
Number of subjects: 10
Study: 10442197

Group type: EXPERIMENTAL
Intervention: Elastomeric infusor (Baxter)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mechanical, electronically controlled pump (CADD‐1, Pharmacia)
Number of subjects: 10